On October 26, 2022 Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, reported the appointment of Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer (Press release, Nimbus Therapeutics, OCT 26, 2022, View Source [SID1234622414]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I am delighted to welcome Nathalie to our leadership team as Nimbus advances multiple potential breakthrough candidates into their next phase of development, including our clinical TYK2 and HPK1 inhibitors," said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. "Nathalie’s strategic leadership and extensive clinical experience will be an asset to our growing clinical development team, and her wide range of experience in the development and commercialization of both small and large molecules in various therapeutic areas is an ideal fit for the breadth of Nimbus’ pipeline."
Dr. Franchimont joins Nimbus from Biogen, where she served as Senior Vice President, Head of Multiple Sclerosis and Immunology Development Unit. She previously held a variety of other leadership roles at Biogen, including leading the Multiple Sclerosis Research and Early Development Unit, the New Indications Research and Early Development Unit and the Immunology Drug Innovation Unit. Prior to joining Biogen, Dr. Franchimont held Medical Affairs and Clinical Development roles at Amgen. A rheumatologist by background, Dr. Franchimont trained at the University of Liège and has held research fellow and research associate roles at the University of Connecticut School of Medicine, Yale University School of Medicine and University of Liège. Dr. Franchimont has served on the Board of Directors of OMass Therapeutics since 2020.
"I am incredibly pleased to join Nimbus at a very exciting time in the company’s history and work with this accomplished team to bring new treatment possibilities to patients," said Dr. Franchimont. "Nimbus has advanced compelling medicines targeting TYK2 and HPK1 to the clinic and is developing strategies to address multiple other highly sought-after targets. NDI-034858, in ongoing Phase 2b trials, is a great example of the power of Nimbus’ approach and I believe it has potential to be a differentiated, best-in-class oral allosteric TYK2 inhibitor for the treatment of psoriasis, psoriatic arthritis and other immune-mediated diseases."